This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zelapar

Valeant Pharmaceuticals International, Inc.

Drug Names(s): Zydis selegiline, Xilopar (Germany), Otrasel (France)

Description: Zelapar is in orally dissolving and absorbed formulation of selegiline. Flashtab technology allows Zelapar dissolution on contact with the tongue and without water, and provides therapeutic selegiline levels in with one-eighth of the customary daily dose. The formulation reduces the concentrations of potentially toxicselegiline amphetamine metabolites. Selegiline is a monoamine oxidase B (MAO-B) inhibitor that prevents the breakdown of dopamine in the brain. Additionally at higher doses selegiline also inhibits MAO-A.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Valeant, Amarin, Elan and Cardinal Health
In February 2004, Valeant acquired North American rights to Zelapar (and apparently rights for the UK, Ireland, and some other non-specified countries) as part of the purchase of Amarin Corporations US-based subsidiary, Amarin Pharmaceuticals. Under terms of a September 2004 amended purchase agreement, Valeant was no longer obligated to pay up to $8 million in milestone payments, but paid an additional $2 million, which was expensed as research and development in 2004 related to Amarin commitment to fund a portion of the Zelapar studies. Valeant remains obligated to make a $10 million milestone payment to the developer of Zelapar upon the attainment of specified sales thresholds.

Amarin had acquired these rights to Zelapar from Elan, who had acquired them from RP Scherer, the developer of the Zydis orally dissolving technology. In December 2004, after the successful...See full deal structure in Biomedtracker

Partners: Perrigo Company PLC Amarin Corporation plc Cardinal Health Inc. Teva Pharmaceutical Industries Ltd.


Zelapar News

Pink Sheet Amarin/Elan Zelapar


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug